MarketInOut Stock Screener Log In | Sign Up

Northwest Biotherapeutics Inc

OTC • Healthcare • Biotechnology • Quote as of 10/30/2026
Northwest Biotherapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeOTC
Market Capitalization255.85 mln
Float1,669 mln
Earnings Date11/13/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

3.09
Highly suspicious

Relative Strength

89 / 100
Strongly outperforming

Pre-Tax Margin

-1,761%
Severely loss-making

ROE

69.98
Exceptional

Altman Z-Score

-28.88
Deeply distressed

Business Description

Northwest Biotherapeutics is a Maryland-based company working to fight cancer by harnessing the body's own immune system. Their core approach involves training specialized immune cells, called dendritic cells, to recognize and attack tumors in individual patients. The company's most advanced treatment targets an aggressive form of brain cancer and has already completed large-scale clinical testing, while a second treatment aimed at hard-to-operate-on tumors has also shown early promise.

Key Fundamentals

EPS-0.03
ROE69.98
RPS0.00
ROIC-30.58
ROA-32.39
Interest Cover-5.34
EBITDA, mln-25.83
EV / EBITDA-12.46
EV / EBIT-11.16
Revenue, mln2.17
EV / Revenue148

Quote Details

Last 0.1700
Change 0.0015 (0.89%)
Open 0.1684
Volume 3,044,812
Turnover 517,618
Average Volume 5,935,919

Financial Ratios

Pre-Tax Profit Margin-1,761
Current Ratio0.04
Price / Sales149
PEG Ratio1.72

Financial Strength

Altman Z-Score-28.88
Piotroski F-Score 4 / 9
Beneish M-Score3.09
Short Ratio4.76
Short % of Float11.84

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 12.06% 93 / 100   
1 Month 11.55% 88 / 100   
2 Months -2.07% 54 / 100   
6 Months -14.68% 43 / 100   
1 Year -27.23% 31 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog